A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV

NCT06564194 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus (RSV)
Infectious Disease

Interventions

BIOLOGICAL: JCXH-108
OTHER: Placebo

Sponsor

Immorna Biotherapeutics, Inc.

Collaborators

[object Object]